A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Cancer

In brief

This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.

Key facts

Study ID

NCT05025085

Run by

Agenus Inc.

People needed

25

Starts

2021-10-04

Expected to finish

2024-04-01

Last updated by the study team

2025-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Providence Cancer Institute — Portland, Oregon, United States
• Local Institution - 165 — Grand Rapids, Michigan, United States
• START Midwest — Grand Rapids, Michigan, United States
• Local Institution - 024 — Southfield, Michigan, United States
• Local Institution - 072 — Cincinnati, Ohio, United States
• University of Cincinnati Cancer Center — Cincinnati, Ohio, United States
• Lifespan Cancer Institute — Providence, Rhode Island, United States
• Local Institution - 0001 — Providence, Rhode Island, United States
• Local Institution - 164 — Dallas, Texas, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States
• MD Anderson Cancer Center Thoracic-Head & Neck Med Onc — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.